Menu
Montecito
Pac Premier
Giving Guide
Loading...
You are here:  Home  >  'Amgen'  -  Page 38
Latest

Amgen beats analyst estimates for fourth quarter revenue

By   /  Thursday, February 2nd, 2017  /  Central Coast Health Watch, Earnings, Latest news, Technology, Tri-County Public Companies  /  Comments Off on Amgen beats analyst estimates for fourth quarter revenue

Thousand Oaks-based biotech giant Amgen reported revenue of $6 billion in the fourth quarter of 2016, besting analyst estimates of $5.74 billion and increasing 8 percent from the fourth quarter of 2015. The world’s largest biotech drug maker posted total revenues of $23 billion on the year, up 6 percent from 2015. Revenue gains were Read More →

Read More →
Latest

Amgen CEO meets with Trump, vows to add 1,600 jobs

By   /  Tuesday, January 31st, 2017  /  Central Coast Health Watch, Latest news  /  Comments Off on Amgen CEO meets with Trump, vows to add 1,600 jobs

Amgen CEO Robert Bradway met with President Donald Trump on Jan. 31 and vowed to add 1,600 jobs, Bloomberg News reported. Trump told biotech leaders at a White House meeting that drug prices needed to come down and he would find a way to streamline the regulatory process. He has discussed having the government negotiate Read More →

Read More →
Latest

Europeans recommend approval of Amgen’s biosimilar of AbbVie’s Humira

By   /  Friday, January 27th, 2017  /  Central Coast Health Watch, Latest news, Technology  /  Comments Off on Europeans recommend approval of Amgen’s biosimilar of AbbVie’s Humira

The European Medicines Agency recommended the approval of the ABP 501, a biosimilar of AbbVie’s Humira (adalimumab), for treatment of inflammatory diseases, Thousand Oaks-based biotech company Amgen announced on Jan. 27. The EMA recommended ABP 501’s use for moderate-to-severe rheumatoid arthritis, psoriatic arthritis, severe ankylosing spondylitis, severe axial spondyloarthritis without radiographic evidence of AS, moderate-to-severe Read More →

Read More →
Latest

Patent ruling in favor of Amgen has shares skyrocketing

By   /  Friday, January 13th, 2017  /  Central Coast Health Watch, Latest news, Tri-County Public Companies  /  Comments Off on Patent ruling in favor of Amgen has shares skyrocketing

This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.

Read More →
Latest

Amgen updates agreement with DaVita for dialysis treatment

By   /  Monday, January 9th, 2017  /  Central Coast Health Watch, Latest news, Tri-County Public Companies  /  Comments Off on Amgen updates agreement with DaVita for dialysis treatment

Thousand Oaks biotech company Amgen entered into a six-year supply agreement with DaVita for dialysis treatments, the company announced on Jan. 9. Under the terms of the new agreement, Amgen will supply DaVita with Epogen and Aranesp for agents to stimulate red blood cells in dialysis treatment in the United States and Puerto Rico. The Read More →

Read More →
Latest

Amgen partners with Immatics Biotechnologies to develop cancer drugs

By   /  Monday, January 9th, 2017  /  Central Coast Health Watch, Latest news, Tri-County Public Companies  /  Comments Off on Amgen partners with Immatics Biotechnologies to develop cancer drugs

Thousand Oaks biotech company Amgen formed a potential $500 million partnership with Immatics Biotechnologies GmbH to research and develop next-generation, T-cell engaging bispecific immunotherapies targeting multiple cancers, the company announced on Jan. 9. Under the terms of the agreement, Immatics will receive $30 million upfront and can receive more than $500 million in development, regulatory Read More →

Read More →
Latest

Amgen shares climb after judge upholds Repatha patents

By   /  Friday, January 6th, 2017  /  Central Coast Health Watch, Latest news, Law  /  Comments Off on Amgen shares climb after judge upholds Repatha patents

A ruling in a patent law case regarding a new anti-cholesterol drug involving Thousand Oaks biotech giant Amgen has skyrocketed Amgen shares. Amgen filed a patent infringement lawsuit against Sanofi and Regeneron in the U.S. District Court of Delaware in October 2014 to block the development and sale of the drug Praluent, which was developed Read More →

Read More →